NCT00327444 - Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Ovarian NeoplasmsAscites

Interventions

DRUG

aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.

DRUG

Placebo

Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.

DRUG

aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.

Trial Locations (9)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey